D
Aldeyra Therapeutics, Inc.
ALDX
$1.91
$0.021.06%
D
Sell
2/2/2024Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D- from E+ on 2/2/2024 due to an increase in the volatility index.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D- from E+ on 2/2/2024 due to an increase in the volatility index.
E
Sell
1/18/2024Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to E+ from D- on 1/18/2024 due to a significant decline in the total return index and volatility index.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to E+ from D- on 1/18/2024 due to a significant decline in the total return index and volatility index.
D
Sell
3/14/2023Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D+ on 3/14/2023 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.1 to 0.11.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D+ on 3/14/2023 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.1 to 0.11.
D
Sell
3/3/2023Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D+ from D on 3/3/2023 due to an increase in the total return index and volatility index.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D+ from D on 3/3/2023 due to an increase in the total return index and volatility index.
D
Sell
2/23/2023Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index. Debt to equity increased from 0.09 to 0.1, and the quick ratio declined from 7.25 to 6.77.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index. Debt to equity increased from 0.09 to 0.1, and the quick ratio declined from 7.25 to 6.77.
D
Sell
8/4/2022Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index.
D
Sell
6/17/2022Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 6/17/2022 due to a decline in the volatility index, total return index and valuation index.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 6/17/2022 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/31/2022Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
D
Sell
5/13/2022Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index and solvency index. Operating cash flow declined 11.19% from -$11.58M to -$12.87M, EBIT declined 7.01% from -$15.4M to -$16.48M, and earnings per share declined from -$0.2712 to -$0.288.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index and solvency index. Operating cash flow declined 11.19% from -$11.58M to -$12.87M, EBIT declined 7.01% from -$15.4M to -$16.48M, and earnings per share declined from -$0.2712 to -$0.288.
D
Sell
5/5/2022Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and valuation index.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and valuation index.
D
Sell
4/20/2022Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index, growth index and volatility index. Operating cash flow declined 37.27% from -$8.43M to -$11.58M.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index, growth index and volatility index. Operating cash flow declined 37.27% from -$8.43M to -$11.58M.
D
Sell
12/14/2021Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D from D+ on 12/14/2021 due to a decline in the volatility index.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D from D+ on 12/14/2021 due to a decline in the volatility index.
D
Sell
11/9/2021Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D+ from D- on 11/09/2021.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D+ from D- on 11/09/2021.
D
Sell
11/8/2021Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D+ on 11/8/2021 due to a decline in the solvency index, growth index and volatility index. The quick ratio declined from 16.84 to 9.74, and EBIT declined 6.18% from -$14.54M to -$15.44M.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D+ on 11/8/2021 due to a decline in the solvency index, growth index and volatility index. The quick ratio declined from 16.84 to 9.74, and EBIT declined 6.18% from -$14.54M to -$15.44M.
D
Sell
7/23/2021Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D+ from D on 7/23/2021 due to a significant increase in the total return index, volatility index and solvency index. The quick ratio increased from 4.26 to 7.97, and debt to equity declined from 0.26 to 0.12.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D+ from D on 7/23/2021 due to a significant increase in the total return index, volatility index and solvency index. The quick ratio increased from 4.26 to 7.97, and debt to equity declined from 0.26 to 0.12.
D
Sell
6/24/2020Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 6/24/2020 due to a noticeable increase in the growth index. Earnings per share increased from -$0.4758 to -$0.3378, and EBIT increased 24.87% from -$12.83M to -$9.64M.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 6/24/2020 due to a noticeable increase in the growth index. Earnings per share increased from -$0.4758 to -$0.3378, and EBIT increased 24.87% from -$12.83M to -$9.64M.
D
Sell
2/21/2020Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 2/21/2020 due to a decline in the volatility index.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 2/21/2020 due to a decline in the volatility index.
D
Sell
2/6/2020Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 2/6/2020 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 35.09% from -$12.81M to -$8.32M.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 2/6/2020 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 35.09% from -$12.81M to -$8.32M.
D
Sell
6/27/2019Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 6/27/2019 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 58.53% from -$7.97M to -$12.63M, and earnings per share declined from -$0.4053 to -$0.5775.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 6/27/2019 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 58.53% from -$7.97M to -$12.63M, and earnings per share declined from -$0.4053 to -$0.5775.
D
Sell
3/29/2019Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 3/29/2019 due to an increase in the solvency index, valuation index and volatility index. Debt to equity declined from 0.05 to 0, and the quick ratio increased from 3.15 to 5.85.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 3/29/2019 due to an increase in the solvency index, valuation index and volatility index. Debt to equity declined from 0.05 to 0, and the quick ratio increased from 3.15 to 5.85.
D
Sell
5/3/2018Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 5/3/2018 due to a decline in the valuation index.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 5/3/2018 due to a decline in the valuation index.
D
Sell
4/18/2018Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 4/18/2018 due to an increase in the valuation index.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 4/18/2018 due to an increase in the valuation index.
D
Sell
4/3/2018Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 4/3/2018 due to a decline in the growth index, valuation index and efficiency index. EBIT declined 40.5% from -$5.02M to -$7.05M, net income declined 39.47% from -$4.99M to -$6.95M, and earnings per share declined from -$0.32 to -$0.3631.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 4/3/2018 due to a decline in the growth index, valuation index and efficiency index. EBIT declined 40.5% from -$5.02M to -$7.05M, net income declined 39.47% from -$4.99M to -$6.95M, and earnings per share declined from -$0.32 to -$0.3631.
D
Sell
11/16/2017Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 11/16/2017 due to an increase in the valuation index, solvency index and efficiency index. Total capital increased 91.5% from $24.67M to $47.24M, the quick ratio increased from 12.23 to 19.8, and debt to equity declined from 0.06 to 0.03.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 11/16/2017 due to an increase in the valuation index, solvency index and efficiency index. Total capital increased 91.5% from $24.67M to $47.24M, the quick ratio increased from 12.23 to 19.8, and debt to equity declined from 0.06 to 0.03.
D
Sell
9/29/2017Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 9/29/2017 due to a decline in the valuation index.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 9/29/2017 due to a decline in the valuation index.
D
Sell
9/14/2017Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 9/14/2017 due to an increase in the volatility index, growth index and efficiency index. Earnings per share increased from -$0.369 to -$0.3507.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 9/14/2017 due to an increase in the volatility index, growth index and efficiency index. Earnings per share increased from -$0.369 to -$0.3507.
D
Sell
3/31/2017Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 3/31/2017 due to a large decline in the efficiency index and solvency index. Debt to equity increased from 0.05 to 0.06, total capital declined 14.88% from $26.98M to $22.97M, and the quick ratio declined from 10.95 to 10.84.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 3/31/2017 due to a large decline in the efficiency index and solvency index. Debt to equity increased from 0.05 to 0.06, total capital declined 14.88% from $26.98M to $22.97M, and the quick ratio declined from 10.95 to 10.84.
D
Sell
4/1/2016Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from E+ on 4/1/2016 due to a large increase in the efficiency index.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from E+ on 4/1/2016 due to a large increase in the efficiency index.
E
Sell
3/28/2016Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to E+ from D- on 3/28/2016 due to a large decline in the volatility index and total return index.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to E+ from D- on 3/28/2016 due to a large decline in the volatility index and total return index.
D
Sell
2/16/2016Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 2/16/2016 due to a decline in the volatility index and total return index.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 2/16/2016 due to a decline in the volatility index and total return index.
D
Sell
2/1/2016Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 2/1/2016 due to an increase in the volatility index and valuation index.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 2/1/2016 due to an increase in the volatility index and valuation index.
D
Sell
11/20/2015Downgrade
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 11/20/2015 due to a substantial decline in the volatility index, growth index and total return index.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to D- from D on 11/20/2015 due to a substantial decline in the volatility index, growth index and total return index.
D
Sell
6/1/2015Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 6/1/2015 due to an increase in the valuation index, volatility index and solvency index. The quick ratio increased from 6.42 to 15.17, and debt to equity declined from 0.2 to 0.09.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D from D- on 6/1/2015 due to an increase in the valuation index, volatility index and solvency index. The quick ratio increased from 6.42 to 15.17, and debt to equity declined from 0.2 to 0.09.
D
Sell
2/2/2015Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D- from E+ on 2/2/2015 due to a significant increase in the volatility index, total return index and growth index. Operating cash flow increased 35.36% from -$894.5 to -$1.21M, and EBIT increased 19.53% from -$1.65M to -$1.97M.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to D- from E+ on 2/2/2015 due to a significant increase in the volatility index, total return index and growth index. Operating cash flow increased 35.36% from -$894.5 to -$1.21M, and EBIT increased 19.53% from -$1.65M to -$1.97M.
E
Sell
11/3/2014Upgraded
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to E+ from E on 11/3/2014 due to an increase in the total return index, solvency index and growth index. Debt to equity declined from -0.03 to 0.12, the quick ratio increased from 3.1 to 9.82, and EBIT increased 32.26% from -$1.24M to -$1.65M.
Aldeyra Therapeutics, Inc. (ALDX) was upgraded to E+ from E on 11/3/2014 due to an increase in the total return index, solvency index and growth index. Debt to equity declined from -0.03 to 0.12, the quick ratio increased from 3.1 to 9.82, and EBIT increased 32.26% from -$1.24M to -$1.65M.
E
Sell
7/28/2014None
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to E from U on 07/28/2014.
Aldeyra Therapeutics, Inc. (ALDX) was downgraded to E from U on 07/28/2014.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
